Table 2.
Univariate and multivariate analysis for risk of relapse and progression-free survival
| Univariate analysis | ||||||
|---|---|---|---|---|---|---|
| Characteristic | Risk of relapse | Progression-free survival | ||||
| HR | 95% CI | P | HR | 95% CI | P | |
| Age (>50 years versus ≤50 years) | 1.1 | 0.7-1.8 | 0.6 | 0.94 | 0.6-1.4 | 0.7 |
| Karnofsky performance status (>80% versus ≤80%) | 0.7 | 0.45-1.2 | 0.2 | 0.5 | 0.3-0.7 | <0.001 |
| FLT3 status at time of transplant (positive versus negative) | 5.1 | 3.1-8.5 | <0.001 | 4.4 | 2.96-6.7 | <0.001 |
| Hematopoietic cell transplant–comorbidity index score (≥4 versus 0/1) | 1.5 | 0.9-2.7 | 0.1 | 1.8 | 1.2-2.9 | 0.009 |
| Disease status at transplant | ||||||
| CR2 versus CR1 | 0.7 | 0.2-2.2 | 0.5 | 1.5 | 0.7-2.96 | 0.3 |
| CR-HR versus CR1 | 4.3 | 2.2-8 | <0.001 | 3.9 | 2.3-6.6 | <0.001 |
| Active morphologic disease versus CR1 | 6.5 | 3.7-11 | <0.001 | 5.9 | 3.7-9.3 | <0.001 |
| Donor source | ||||||
| Matched unrelated versus matched related | 1.6 | 0.9-2.8 | 0.09 | 1.6 | 1.0-2.6 | 0.04 |
| Mismatched unrelated versus matched related | 1.2 | 0.5-2.9 | 0.6 | 1.9 | 0.97-3.5 | 0.06 |
| Haploidentical versus matched related | 0.5 | 0.1-2.2 | 0.4 | 0.9 | 0.4-2.5 | 0.9 |
| Cord blood versus matched related | 1.9 | 0.9-4.2 | 0.1 | 2.2 | 1.2-4.3 | 0.01 |
| Graft source, excluding cord blood (peripheral blood versus bone marrow) | 0.9 | 0.6-1.5 | 0.7 | 0.8 | 0.6-1.3 | 0.4 |
| FLT3 mutation type (ITD versus TKD mutation at 835) | 2.5 | 1.0-6.3 | 0.05 | 1.99 | 1.0-3.9 | 0.05 |
| Conditioning intensity (reduced intensity versus myeloablative) | 1.1 | 0.6-2.0 | 0.8 | 1.2 | 0.7-1.9 | 0.5 |
| Multivariate analysis | ||||||
|---|---|---|---|---|---|---|
| Characteristic | Risk of relapse | Progression-free survival | ||||
| HR | 95% CI | P | HR | 95% CI | P | |
| CR-HR and FLT3 negative | 2.9 | 1.2-7.2 | 0.02 | NS | ||
| CR-HR and FLT3 positive | 7.5 | 3.4-17 | <0.001 | 7.2 | 3.7-14 | <0.001 |
| Active morphologic disease present at time of transplant | 7 | 3.9-12 | <0.001 | 4.5 | 2.8-7.1 | <0.001 |
| Karnofsky performance status ≤80 | 2.1 | 1.4-3.3 | <0.001 | |||
| Hematopoietic cell transplant–comorbidity index score ≥4 | 1.6 | 0.99-2.6 | 0.05 | |||
| Unrelated donor | 1.7 | 0.98-2.8 | 0.06 | 1.6 | 0.99-2.4 | 0.05 |
HR: hazard ratio; CI: confidence interval; CR1: first complete remission; CR2: second complete remission; CR-HR: high-risk complete remission; ITD: internal tandem duplication; TKD: tyrosine kinase domain; NS: not significant